SARC023 is a Phase I/II Trial of Ganetespib in combination with the mTOR inhibitor sirolimus for patients with recurrent or refractory sarcomas including unresectable or metastatic malignant peripheral nerve sheath tumors.

TYPE OF SARCOMA: Unresectable or metastatic sporadic or neurofibromatosis type 1 (NF1) associated MPNST
DRUG: Ganetespib in combination with Sirolimus


Back to top